Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23627355 | 0.82 | MAOB (0.43) | MAOBHSD17B2PSMB5PSMB8CA2 | |
| SCHEMBL14270019 | 0.79 | TSHR (0.47) | LMNAMAOBHSD17B2PSMB5PSMB8 | |
| SCHEMBL2960730 | 0.79 | MAOB (0.43) | MAOBHSD17B2PSMB5PSMB8CA2 | |
| SCHEMBL28392768 | 0.79 | MAOB (0.43) | MAOBHSD17B2PSMB5PSMB8CA2 | |
| SCHEMBL28394138 | 0.79 | MAOB (0.43) | MAOBHSD17B2PSMB5PSMB8CA2 | |
| SCHEMBL29756135 | 0.78 | MAOB (0.40) | MAOBHSD17B2PSMB5PSMB8CA2 | |
| SCHEMBL4139411 | 0.76 | MAOB (0.45) | MAOBHSD17B2PSMB5PSMB8CYP2C9 | |
| SCHEMBL4146586 | 0.75 | MAOB (0.44) | MAOBHSD17B2PSMB5PSMB8CA2 | |
| SCHEMBL24898027 | 0.75 | MAOB (0.43) | LMNAMAOBHSD17B2PSMB5PSMB8 | |
| SCHEMBL4152831 | 0.74 | MAOB (0.47) | MAOBHSD17B2PSMB5PSMB8CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537122-B9 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1537122-B1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1537122-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6800637-B2 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-07-15 | — | — | US | disclosed |
| WO-2004024734-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | HTR5A, TPH1, DBH | LMNA 949/4885MAOB 59/4885HSD17B2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.